Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Payables: 2011-2025

Historic Payables for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2025 value amounting to $835,000.

  • RedHill Biopharma's Payables fell 56.33% to $835,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $7.2 million, marking a year-over-year decrease of 43.22%. This contributed to the annual value of $1.2 million for FY2024, which is 64.37% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Payables is $835,000, which was down 28.51% from $1.2 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Payables high stood at $119.4 million for Q4 2022, and its period low was $835,000 during Q2 2025.
  • Moreover, its 3-year median value for Payables was $2.5 million (2023), whereas its average is $2.4 million.
  • In the last 5 years, RedHill Biopharma's Payables grew by 25.36% in 2022 and then plummeted by 97.26% in 2023.
  • RedHill Biopharma's Payables (Quarterly) stood at $95.3 million in 2021, then grew by 25.36% to $119.4 million in 2022, then tumbled by 97.26% to $3.3 million in 2023, then slumped by 64.37% to $1.2 million in 2024, then plummeted by 56.33% to $835,000 in 2025.
  • Its last three reported values are $835,000 in Q2 2025, $1.2 million for Q4 2024, and $1.9 million during Q2 2024.